To compare the prognosis of locally advanced upper tract urothelial carcinoma (UTUC) and bladder tumor (BT) in patients treated with radical surgeries. Methods: We retrospectively reviewed records on 228 consecutive UTUC patients and 174 consecutive BT patients between 2000 and 2012, both with high-stage diseases. Overall and cancer-specific survival was compared using the Kaplan-Meier method. The values of prognostic factors were evaluated by Cox regression analysis. Results: No difference was observed in age and tumor size between the two groups. The UTUC group had significantly more frequent hydronephrosis than the BT group (48.2% vs. 1.1%, P=0.000). However, the UTUC group showed significantly less frequent high grade (92.1% vs. 98.9%, P=0.002), multifocality (27.2% vs. 53.4%, P=0.000) and lymph nodal involvement (19.3% vs. 32.8%, P=0.002) than the BT group. UTUC had statistically better 5-year cancer-specific survival rate (61.0% vs. 49.8%, P=0.008) and overall survival rate (58.3% vs. 37.4%, P<0.001) than BT. In multivariate analysis, tumor location (HR =0.553), multifocality (HR =0.717), lymph node status (HR =1.920) and hydronephrosis (HR =1.673) were independent risk factors of cancer-specific death. Multivariate analysis revealed that tumor location (HR =0.407), lymph node status (HR =1.651) and hydronephrosis (HR =1.577) were independent risk factors of overall death. Conclusions: Our data suggest that locally invasive UC behaves differently in the upper and lower urinary tracts. UTUC has a better prognosis than BT when stage and grade are considered simultaneously. Lymph node involvement has severe influences on clinical outcomes of urothelial carcinoma which is consistent with other previous studies. Objective: Multilocular cystic renal cell carcinoma (MCRCC) is a distinct subtype of clear cell renal cell carcinoma. Different from other types of renal cancers, MCRCC has a favorable outcome. The real incidence of MCRCC using the new diagnostic criteria is yet unclear. Large scale study is therefore needed to further identify the characteristics of MCRCC. Methods: A total of 77 MCRCC cases were identified following the 2004 WHO diagnostic criteria in our institute. Their clinical and radiographical characteristics, surgical management, pathological features, and outcomes were retrospectively reviewed. Results: The incidence of MCRCC in our renal cell carcinoma (RCC) patients was 1.8% (77/4,189). After a median follow-up period of 51 months, no tumor recurrence or metastasis was found. Conclusions: The incidence of MCRCC in RCC patients is low. Most cases showed no symptoms, and accurate diagnosis is difficult before surgery. MCRCC carries an excellent prognosis after surgical treatment, regardless of the tumor size. Partial nephrectomy should be considered as the preferable surgical approach for the management of MCRCC. The
